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Vectors derived from adeno-associated virus (AAV) are 
promising candidates for neural cell transduction in vivo 
because they are nonpathogenic and achieve long-term 
transduction in the central nervous system. AAV serotype 
2 (AAV2) is the most widely used AAV vector in clinical 
trials based largely on its ability to transduce neural cells 
in the rodent and primate brain. Prior work in rodents 
suggests that other serotypes might be more efficient; 
however, a systematic evaluation of vector transduction 
efficiency has not yet been performed in the  primate 
brain. In this study, AAV viral vectors of serotypes 1–6 with 
an enhanced green-fluorescent protein (GFP) reporter 
gene were generated at comparable titers, and injected 
in equal amounts into the brains of Chlorocebus sabaeus. 
Vector injections were placed in the substantia nigra 
(SN) and the caudate nucleus (CD). One month after 
injection, immunohistochemistry for GFP was performed 
and the total number of GFP+ cells was calculated using 
unbiased stereology. AAV5 was the most efficient vector, 
not only transducing significantly more cells than any 
other serotype, but also transducing both NeuN+ and 
glial-fibrillary-acidic protein positive (GFAP+) cells. These 
results suggest that AAV5 is a more effective vector than 
AAV2 at delivering potentially therapeutic transgenes to 
the nigrostriatal system of the primate brain.
Received 18 June 2009; accepted 17 November 2009; published online 
15 December 2009. doi:10.1038/mt.2009.286
IntroductIon
Viral vectors can be useful tools for expressing desired genes in 
brain cells to achieve therapeutic benefit. Adeno-associated virus 
(AAV), a nonpathogenic parvovirus, has become the most widely 
used vector in gene therapy applications in human. Twelve  vector 
serotypes have been identified, and are of particular interest, 
because of capsid-associated tissue tropisms identified in some of 
them.1–3 These tropisms have been described in rodents, but work 
in nonhuman primate and human clinical trials has been more 
circumscribed. Over 40 clinical trials have been approved using 
AAV vectors, all of them are serotype 2, or using AAV serotype 
2 (AAV2) vector genomes and AAV1 capsids.4 There has been no 
systematic exploration of tissue tropism or vector transduction 
efficiency using AAV vectors of multiple serotypes in the non-
human primate, which has led to limitations in the vectors avail-
able for clinical use.
The goal in human neurosurgical procedures delivering viral 
vectors to the brain is to make as little perturbation of brain tissue 
as is possible while delivering the needed gene for the appropri-
ate duration. Viral vectors that can generate a large overall area 
of transduction and have a tropism for the desired cell type may 
allow for the delivery of the smallest possible amount of  vector, 
resulting in maximal gene delivery while minimizing tissue dam-
age, inappropriate spread, or the possibility of incorporation 
into the host genome. In this study, we have generated high-titer 
 vectors from AAV serotypes 1–6 with a green-fluorescent protein 
(GFP) reporter gene, and injected those vectors into the substan-
tia nigra (SN) and caudate nucleus (CD) of old world nonhuman 
primates, Chlorocebus sabaeus, the St Kitts subspecies of African 
green monkey. Tissue sections throughout the extent of the injec-
tion site were analyzed for GFP expression by immunohistochem-
istry, and GFP+ cells were counted using unbiased stereology. We 
labeled and counted the numbers of vector-transduced cells by 
serotype, determined the vector with greatest transduction effi-
ciency for these two regions of the nonhuman primate brain, and 
identified the most promising of these vector subtypes for use in 
human clinical trials targeting the nigrostriatal system.
results
Viral vectors of AAV serotypes 1–6 with the gene for GFP were 
injected into the brains of St Kitts green monkeys. The animals 
survived for 30 days in good health with postoperative clinical 
evaluation showing no evidence of behavioral abnormalities, loss 
of appetite, weight loss, or other abnormalities. Brain tissue pro-
cessed for immunohistochemistry using the antibody to GFP and 
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a 3,3′-diamino-benzidine (DAB) secondary showed numerous 
cells around the injection site that contained DAB chromogen. 
Vector injections of 1 × 1012 viral genomes/ml were placed into SN 
(Figure 1) and CD (Figure 2), and transduced cells were detected 
in those regions and along the injection tract, with no evidence of 
spillage into the ventricles.
Transduction efficiency was measured by determining both the 
number of GFP+ cells and the volume of tissue containing GFP+ 
cells. The correlation between these parameters was strongly posi-
tive in the CD (Pearson correlation coefficient 0.88, P < 0.0001, 
n = 23) and less strongly positive in the SN (Pearson correlation 
coefficient 0.67, P < 0.0001, n = 27). AAV serotype 5 transduced 
1.85 × 105 cells in CD and SN, a significantly higher number of 
cells than any other serotype (analysis of variance, degrees of free-
dom (5.23), F = 7.88, P < 0.0002; post hoc Student–Newman–Keuls 
test P < 0.05) (Figure 3a).
Both AAV5 and AAV1 resulted in significantly higher trans-
duction volume than other serotypes (analysis of variance, 
degrees of freedom (5.23), F = 21.51, P < 0.0001; post hoc Student–
Newman–Keuls test P < 0.05) (Figure 3b) generating 40.87 and 
38.61 mm3 of transduced tissue, respectively. These  volumes were 
significantly higher than those generated by any other serotype 
(8.22–18.22 mm3) (Figure 3b). AAV1 and AAV5 were not  different 
from each other in volume of transduction. There were signifi-
cant differences in volume of transduction between CD and the 
SN when all vectors were analyzed together (analysis of variance, 
degrees of freedom (1.15), F = 20.1, P < 0.0004), but this was not 
due to any specific serotype. Cell counts were not significantly dif-
ferent between the two targets for all serotypes. Density (count/
volume) was also significantly different between CD and SN for 
all serotypes together (analysis of variance, degrees of freedom 
(1.15), F = 11.8, P < 0.004), but this was not due to any serotype 
alone. There were no significant differences in density between 
any of the serotypes.
In order to determine what types of cells were being transduced 
by AAV5, we performed fluorescence immunohisto chemistry 
for multiple labels on transduced tissue that was evaluated using 
confocal microscopy (Figure 4). We also evaluated the type of 
cells transduced by AAV1, because it has the largest effects next 
to AAV5, and by AAV2, because it is the most often used vector 
for gene therapy applications to date. The antibody for GFP was 
visualized with a fluorescein isothiocyanate secondary (green), 
the antibody for glial-fibrillary-acidic protein (GFAP) with CY5 
(blue), and the antibody for NeuN with Rhodamine Red-X (red). 
Figure 1 Bright-field microscopy of immunohistochemistry for GFP on transduced substantia nigra tissue. Tissue that has been transduced with 
vectors of each serotype (by column) is shown in progressive magnifications (by row) with boxes in low power images showing the area magnified 
in subsequent rows. All vectors were able to transduce neural cells to produce the gene product GFP. Bars are 1 mm in the top row, 100 µm in the 
middle row, and 10 µm in the bottom row. GFP, green-fluorescent protein.
Figure 2 Bright-field microscopy of immunohistochemistry for GFP on transduced caudate tissue. Tissue that has been transduced with vectors 
of each serotype (by column) is shown in progressive magnifications (by row) with boxes in low power images showing the area magnified in sub-
sequent rows. All vectors were able to transduce neural cells to produce the gene product GFP. Bars are 1 mm in the top row, 100 µm in the middle 
row, and 10 µm in the bottom row. GFP, green-fluorescent protein.
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All vectors transduced neurons and glial cells, but to a different 
extent. Although AAV2 transduced more neurons than glial cells 
(~65% of transduced cells that could be assigned a phenotype were 
NeuN+ neurons), AAV5 transduced neurons and glial cells with 
apparently equal efficiency (~47% were GFAP+, 53% NeuN+).
dIscussIon
This study systematically compares the transduction efficiency 
of AAV vector serotypes 1–6 in the nonhuman primate brain. 
All six serotypes of AAV were able to transduce endogenous 
cells to generate the reporter gene GFP. AAV3 was the least 
reliable of the vectors, with several injections resulting in no 
detectable transduced cells at 1 month; total transduced cell 
numbers were the lowest with this serotype. AAV5 was the most 
 efficient of the vectors studied (Figure 3), labeling the most cells 
over the largest volume, by a very large margin, regardless of 
injection location in the brain. AAV1 also labeled cells over a 
larger volume than any of the other serotypes except AAV5. 
Furthermore, AAV5 effectively transduced glial cells as well as 
neurons, whereas AAV2 is generally considered to have a greater 
tropism for neurons.5–9 This finding agrees with the results of 
previous studies in rodents: in mice and rats AAV5 led to a 
higher number of transduced cells and demonstrated the ability 
to infect glial cells stably and effectively, thus being superior to 
serotypes 1, 2, 6, 7, 8, and 9 (ref. 10–14). These findings indicate 
that using AAV5 as a vector for gene delivery instead of AAV2 
could improve gene delivery in the human central nervous sys-
tem considerably, especially when the transgene produces a pro-
tein normally manufactured in glial cells.
The present study was carried out in a large number of  monkeys, 
all evaluated at 30 days after vector injection. It is possible that 
some serotypes might lead to more gene expression over  longer 
periods of time. Most AAV serotype capsids share >80% amino 
acid similarity, yet these differences can lead to large differences 












































































Figure 3 Quantification of vector transduction. (a) The numbers of 
transduced cells expressing GFP,  determined by unbiased stereology, are 
shown for each vector serotype in the CD and the SN. The number (n) of 
monkeys studied was as follows: for AAV1, n = 4 CD, n = 4 SN; AAV2, n 
= 2 CD, n = 6 SN; AAV3, n = 5 CD, n = 5 SN; AAV4, n = 3 CD, n = 3 SN; 
AAV5, n = 5 CD, n = 6 SN; AAV6, n = 4 CD, n = 3 SN. AAV5 transduced 
significantly (*) more cells than any other vector type in both CD and SN. 
(b) The volume of tissue (mm3) containing transduced cells expressing 
GFP is shown by serotype in CD and SN. AAV1 and AAV5 transduced 
significantly (*) more  tissue volume than other vectors studied. AAV, ade-
no-associated virus; CD, caudate nucleus; GFP, green-fluorescent protein; 
SN, substantia nigra.
Figure 4 confocal microscopy of fluorescence immunohistochemistry for neural phenotypes in tissue transduced by AAV1, AAV2, and AAV5. 
Tissue was labeled with the antibody to GFP (green), the neuronal marker NeuN (red), and the glial marker GFAP (blue). Merged images are shown 
in the left column (and again at higher power in the far right column), followed by separated images, and show several yellow cells at yellow arrows 
indicating NeuN+ cells (red) that are also GFP+ (green). Blue arrows point to GFAP+ cells (blue) that are not GFP+, and red arrows indicate NeuN+ 
(red) cells that are not GFP+. In the case of AAV5, there are also aqua arrows that indicate GFAP+ (blue) cells that are also GFP+ (green). Bar = 100 µm. 
AAV, adeno-associated virus; GFP, green-fluorescent protein; GFAP, glial-fibrillary-acidic protein.
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of over 100 AAV variants recovered from human and nonhuman 
primates, with <62% amino acid similarity to AAV1–4 and AAV6 
(ref. 15). Moreover, AAV5 demonstrates a distinct combination 
of characteristics that are likely responsible for the efficiency of 
this serotype;5,6 it binds to the N-linked form of α(2,3) sialic acid,7 
uses platelet-derived growth factor receptor8 and has the potential 
for retrograde transport.9 Although we did see what might have 
been retrograde transport in monkeys that were injected into CD 
in one hemisphere, and the SN in the other, we did not evalu-
ate retrograde transport systematically because we did not have 
enough animals injected in this way across serotypes for meaning-
ful comparisons.
Even though it has proven to be an effective vector in the 
nonhuman primate, AAV5 may not be the most efficient vector 
at transducing neural cells across mammalian species. In their 
study on feline brain Vite et al.16 found AAV5 to be so inefficient 
that direct injection into the brain failed to transduce any cells.16 
In the canine brain AAV2 and AAV8 have been found to be effec-
tive at neural transduction17,18 although, just as in human and 
nonhuman primate, due to the lack of studies of the other AAV 
serotypes in this species, AAV2 is the most widely used vector 
system in canine brain.
Both old and new world nonhuman primates have received 
direct injection of AAV2 vector into the brain, including 
macaque,19–21 cynomolgus,17 and rhesus monkeys22 and transduc-
tion of neural cells has been described in all of them. Although 
other serotypes of AAV vectors are rarely used, AAV1 has been 
used successfully to transduce neural cells in macaque monkey20 
and pseudotyped vectors AAV2/1 and AAV2/5 have been used 
successfully for transduction of neural cells in macaque brain.19 
Interestingly, pseudotyped vectors AAV2/1 and AAV2/5 when 
injected into the macaque striatum showed greater vector copy 
numbers than AAV2. This finding correlates well with our obser-
vation that AAV2 performed unimpressively in the caudate and 
was surpassed by both serotypes 1 and 5 in numbers of cells 
transduced.
Of the seven active clinical trials using AAV vectors in human 
brain, five are directed at Parkinson’s disease therapeutics and all 
have used AAV2. Our study and that of others19 indicate that 
AAV2 is inefficient at transducing neural cells in the striatum. 
In our study, AAV2 was surpassed in transduction efficiency 
by every other serotype injected into the CD except for AAV3. 
AAV5 transduces more cells, and therefore more glial cells than 
any other vector studied, making it a superior vector for use in 
the delivery of glial-derived neurotrophic factor family ligands 
to the SN and CD of primates. Additionally, using AAV5 may 
actually be safer than using AAV2, having a decreased risk of 
crossreactions with pre-existing antibodies. Antibodies against 
AAV, predominantly against serotype 2, are present in 50–80% of 
the population23,24 and have caused problems in previous clinical 
studies.25,26
AAV5 and AAV1 transduce cells over a greater volume of 
 tissue than AAV2, AAV3, AAV4, and AAV6 (Student–Newman–
Keuls test at P < 0.05), and AAV5 transduces more cells than any 
of the other serotypes (P < 0.05 by Student–Newman–Keuls test). 
Combined with possible retrograde transport to the SN (which 
may depend on the extent of the destruction of the nigrostriatal 
pathway), these greater effects could allow the reduction of viral 
protein load for achieving an equivalent effect.
In summary, the AAV5 vector is more efficient than AAV2 in 
the nonhuman primate brain, resulting in a far greater  number 
of cells transduced for a given viral load. Using a viral vector 
with greater efficiency at transducing the desired cell type could 
 provide an advance for delivery of therapeutic genes to the nigros-
triatal system.
MAterIAls And Methods
All animal work complied with National Research Council guidelines and 
was approved by the Axion Research Foundation’s animal care and use 
committee.
Vector construction. The vector used in this study was the TRUF-eGFP 
vector. This vector contains the GFP gene driven by the cytomegalovirus 
promoter. The TRUF-eGFP vector was used for all viral preps in conjunc-
tion with the appropriate AAV helper plasmid for each respective AAV 
serotypes 1–6 used in the experiments.
Vector production. The pTRUF-eGFP vector was packaged into vector 
particles with AAV serotypes of 1–6 at the University of North Carolina 
Vector Laboratories. Vector particles were manufactured as described 
in detail in ref. 27. Briefly, human embryonic kidney-293 cells grown to 
80–90% confluent in Dulbecco’s modified Eagle’s medium + 10% fetal 
bovine serum, 37 °C, 5% CO2 are transfected with TRUF-eGFP, the XX680 
Adenoviral helper plasmid and an AAV helper plasmid (pAAV1, pAAV2, 
pAAV3, pAAV4, pAAV5, or pAAV6, depending on which serotype is 
being prepared) using polyethylenimine as the transfection reagent.
Cells are harvested 48 hours later, lysed in a hypotonic buffer 
(10 mmol/l HEPES, 1.5 mmol/l MgCl2, 10 mmol/l KCL, and 350 mg 
of spermine/l), and then homogenized in a Kontes glass homogenizer 
(Kimball Chase, Vineland, NJ). The resulting nuclei suspension is then 
clarified by centrifugation, sonicated for 25 pulses with a Branson 
sonifier (cycle 50, output 5) and then incubated at 37 °C with 10 mg/ml of 
benzonase for 30–60 minutes.
Nuclear lysates were centrifuged through a CsCl gradient, and peak 
vector fractions were subjected to a second CsCl centrifugation step. The 
pooled peak fractions are then dialyzed in sterile Pierce Slide-A-Lyser 
cassettes twice against phosphate-buffered saline for 2 hours each (total 
dilution factor of 1:1 × 106). Following purification the individual batches 
of vector are stored at −80 °C until used. Titers of vector genomes in the 
viral preparations were determined using the dot-blot method.27 Viral titers 
between the different preps ranged from 2–4 × 1012 vg/ml which is within 
the margin of error for the assay. Using these manufacturing conditions, 
vectors are consistently produced with minimal contamination of cellular 
proteins (see representative preparations in Supplementary Figure S1). 
Viral preps tested for residual CsCl by atomic absorption has shown that 
these methods yield stocks of virus with ≤2 ng of residual CsCl per 1 × 1012 
vector genomes (data not shown).
Stereotactic surgeries. Fully mature adult St Kitts (African) green mon-
keys (C. sabaeus), with no stigmata of advanced age, were anesthetized 
with ketamine (10 mg/kg intramuscularly) and sodium pentobarbital 
(15–25 mg/ kg intravenously), intubated and the scalp was prepped, shaved, 
and mounted into a stereotactic frame using sterile technique. The animal 
was monitored for vital signs, electrocardiography, pO2, temperature and 
given a 30–50 ml/hour intravenous infusion of Lactated Ringer’s solution. 
Each animal received 300,000 Units of Flocillin before surgery. After the 
animal was anesthetized to a level that showed no deep pain responses, 
the scalp was incised. Small 1–2 mm holes in the cranium were drilled at 
the desired coordinates (David Kopf, Tujunga, CA). A 22-gauge needle 
connected to a Hamilton syringe (Hamilton, Reno, NV) was lowered 
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through drilled holes to the desired depth, and left in situ for 2 minutes 
before and after injection. The vector-loaded 100-µl Hamilton syringe was 
driven by a perfusion pump delivering vector at 1 µl/minute (Stoelting 
Instruments, Wood Dale, IL) for 10 minutes, and a total of 10 µl of vec-
tor was delivered to each target. Targets were the left or right CD and left 
or right SN. A sorbitol control injection was made on the same structure 
on the opposite side in some animals. The needle was slowly withdrawn 
(1 mm/min) over a period of 5 minutes. Animals survived for 30 days 
before killing after induction with ketamine (10 mg/kg) followed by an 
overdose of pentobarbital solution given until loss of deep corneal reflexes 
(usually 50–100 mg/ kg intravenously).
DAB immunohistochemistry. Animals were perfused with heparinized 
saline, followed by 4% paraformaldehyde, and brains were removed. 
Blocks of tissue surrounding the injection target were isolated, post-
fixed, and immersed in 30% sucrose. Coronal sections of blocks of tissue 
for DAB immunohistochemistry were cut at 50 µm at room temperature 
on a vibratome. Free-floating sections comprising every fourth section 
were stored in buffer at 4 °C. One series, or every fourth section, was 
immunolabeled for GFP using a mouse monoclonal antibody against 
GFP (Invitrogen # A11120 at 1:250; R&D Systems, Minneapolis, MN). 
GFP immunoreactivity was visualized using biotinylated horse anti-goat 
immunoglobin G (BA-9500 at 1:250; Vector Laboratories, Burlingame, 
CA), and the ABC technique with nickel-intensified DAB as chromagen. 
Sections were examined under a light microscope, and brains in which 
the injection tract was found to be well placed within the target region 
were analyzed.
Fluorescence immunohistochemistry. Triple label fluorescence immuno-
histochemistry was performed on frozen sections of free-floating caudate 
tissue that were cut on a sliding microtome at 40 µm thickness. Sections 
were permeabilized and blocked with 0.3% triton and normal donkey 
serum in potassium phosphate-buffered saline buffer. Primary antibodies 
generated in rabbit, mouse, and guinea pig were diluted in triton buffer 
and applied together onto tissue sections for 72 hours at 4 °C. Sections were 
then rinsed, and incubated in secondary antibodies for 1 hour at room 
temperature. Sections were rinsed, mounted onto gel coated slides, and 
coverslipped using a PVA DABCO mountant.28 Antibodies used were: 
rabbit anti-GFP (1:100, AB3080; Millipore, Temecula, CA); guinea pig 
anti-GFAP (1:250, #031223; Advanced Immunochemicals, Long Beach, 
CA); mouse anti-NeuN (1:100, MAB377; Millipore); secondary antibodies 
used were: donkey-anti-guinea pig CY5, donkey anti-mouse- Rhodamine 
Red-X, and donkey anti-rabbit-fluorescein isothiocyanate (Jackson 
ImmunoResearch, West Grove, PA). Tissue sections were examined under 
a fluorescence microscope equipped with confocal lasers (Zeiss LSM510; 
Zeiss, Thornwood, NY), and images captured using LSM 510 software 
(Zeiss). Images were arranged using Adobe Photoshop (Adobe Systems, 
San Jose, CA).
Stereology: cell counts, volume, and transduction efficiency (density). We 
quantified the number of GFP+ cells and volume of tissue occupied by GFP 
immunoreactivity using Stereo Investigator 7 software (MicroBrightField, 
Williston, VT). Counts were made from at least three animals per serotype/
target area. Every fourth section was analyzed using the optical  fractionator 
probe. The area containing concentrated GFP immuno reactivity was out-
lined at ×2.5 magnification and GFP+ cells were counted at ×20. The 
 volume of spread of concentrated GFP immuno reactivity was determined 
by multiplying the area of the outline by the section thickness and the 
 sampling  interval, using the Cavalieri method.29 Density was determined 
by dividing the cell count by the volume.
Phenotype. To determine the identity of GFP+-transduced cells in  tissue, 
we performed triple-labeling immunofluorescence with the  antibodies 
to GFP, NeuN, and GFAP. We took confocal photomicrographs of 
nonadjacent sections and counted at least 33 cells from each of three 
 animals per serotype for a total of at least 100 cells. The cells were scored 
as NeuN+, GFAP+, or undetermined. Percentages of neurons and glial 
cells were then calculated.
suPPleMentArY MAterIAl
Figure S1. Silver stained polyacrylamide gel electrophoresis (PAGE) of 
AAV GAP vectors of different serotypes.
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